BiotechTube
Metastate Metabolomics

Metastate Metabolomics

Zurich, Europe - Other· Est.
metastate.bio
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Founded in 2019 and based in Zurich, Metastate Metabolomics has developed the 'Metastate Brain,' a decision system designed to compress uncertainty in expensive biological R&D. The company offers focused programs that help teams move from data overload to confident next steps, delivering ranked hypotheses and minimum experiment sets. Its business model is centered on project-based engagements rather than traditional software licenses, targeting high-stakes decisions in industrial biotech and diagnostics.

MetabolicOncology

Technology Platform

Metastate Brain: A decision intelligence system that combines constraints, mechanistic reasoning, and data signals to rank hypotheses and design minimum experiment sets for biological R&D.

Opportunities

The company is positioned to capitalize on the growing inefficiency in biotech R&D, where data abundance meets experimental bottleneck.
The expansion of industrial biotechnology (precision fermentation) provides a large addressable market for its Bioprocess Diagnostic Sprint.
The Peptide-Lab program offers a pathway to transition from service fees to potential asset-based value capture.

Risk Factors

Scalability is a key risk due to its services-heavy, program-based model.
It faces adoption challenges against entrenched internal processes and competition from both consultancies and AI platforms.
The quality of its output is highly dependent on client-provided problem framing and data inputs.

Competitive Landscape

Metastate competes with traditional bioprocess consulting firms, DOE software providers (e.g., JMP, Design-Expert), and broad AI-for-drug-discovery platforms (e.g., Recursion, Exscientia). Its differentiation is a focused, decision-theory-based approach that delivers specific, actionable experiment plans rather than general software or open-ended consulting.

More companies in Diagnostics & Precision Medicine →More companies in Europe - Other →